Revised EU Guide Addresses Ambiguities In Reporting of Safety Info From Trials
Executive Summary
The pharmaceutical industry is hoping that changes to the EU guideline on the management and presentation of reference safety information (RSI) in clinical trial applications will help companies struggling with new regulatory focus on this complex subject.